Results 121 to 130 of about 25,087 (209)

Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management

European Journal of Haematology, Volume 116, Issue 2, Page 116-128, February 2026.
ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli, E. Carazzai, B. Bugnotto, F. Bellinato, M. Krampera, C. Visco   +5 more
wiley   +1 more source

Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway

Cell Death Discovery
Venetoclax, an inhibitor that selectively targets B cell lymphoma-2 (BCL-2) that has been approved for treating adult acute myeloid leukemia (AML) in combination with hypomethylating agents.
Xibao Yu, Yan Wang, Jiaxiong Tan, Yuchen Li, Pengyue Yang, Xuan Liu, Jing Lai, Yue Zhang, Letong Cai, Yinfeng Gu, Ling Xu, Yangqiu Li   +11 more
doaj   +1 more source

Therapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review [PDF]

Clin Case Rep
ABSTRACT With the improvement of survival in multiple myeloma (MM), therapy‐related acute myeloid leukemia (t‐AML) has emerged as a clinically relevant second primary malignancy (SPM). We report a case of MM evolving into t‐AML after multi‐agent chemotherapy and review the literature on therapy‐related leukemias in MM.
Chen S, Hu J, Zhang Q, Mao L, Jiang Q, Qian C, Zhang W, Jin K, Li J, Wang J, Zhao Y.   +10 more
europepmc   +2 more sources

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents

European Journal of Haematology, Volume 116, Issue 2, Page 160-168, February 2026.
ABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Ernesto Vigna, Antonella Bruzzese, Enrica Antonia Martino, Andrea Corsonello, Santino Caserta, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, Volume 158, Issue 2, Page 342-356, 15 January 2026.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study

Therapeutic Advances in Hematology
Background: The response rate of traditional first-line induction chemotherapy (IC) for newly diagnosed acute myeloid leukemia needs to be improved, but it is not clear whether adding venetoclax or hypomethylating agents (HMAs) to IC will improve the ...
Fangfei Xu, Kuangguo Zhou, Duanhao Gong, Wei Huang   +3 more
doaj   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models [PDF]

, 2016

core   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source